Efficacy of Imatinib on Advanced and Refractory Desmoid Tumors: A Retrospective Study
Received Date : 03 Dec 2021
Accepted Date : 22 Apr 2022
Available Online : 12 May 2022
Muhammed Mustafa ATCIa, Orçun CANc, Şaban SEÇMELERa, Abdullah SAKİNa, Seval AYb, Şener CİHANa, Oğuzhan SELVİa, Çağlayan GEREDELİa
aDepartment of Medical Oncology, University of Health Sciences Prof. Dr. Cemil Taşcıoğlu City Hospital, İstanbul, Türkiye
bDepartment of Medical Oncology, İstanbul Medeniyet University Göztepe Education and Research Hospital, İstanbul, Türkiye
cDepartment of Medical Oncology, İstinye University Hospital Liv Hospital Bahçeşehir, İstanbul, Türkiye
Doi: 10.37047/jos.2021-87391 - Article's Language: EN
J Oncol Sci. 2022;8(2):63-8
ABSTRACT
Objective: Our study aimed to analyze imatinib’s efficacy, tolerability, and safety in treating naive patients with unresectable
and progressive desmoid tumors. Material and Methods: The data of patients who were ≥18 years old diagnosed with desmoid tumors treated
with imatinib were evaluated retrospectively regarding their demographic features, comorbidities, disease stage, pathological features of the
tumor, and response rates and progression-free survival (PFS). Results: In our study, 36 patients with advanced desmoid tumors receiving imatinib
with a median age of 28 [interquartile range (IQR): 21-40] of whom 58.3% were female were included. The patient’s complete response,
partial response, stable disease, and progressive disease with imatinib 800 mg/day were 13.9%, 44.4%, 27.7%, and 13.9%, respectively. The
Grade-3 adverse events, including neutropenia (n=3, 8.3%) and rash (n=3, 8.3%), were relieved after dose reduction. The median PFS was 29
months (95% confidence interval, 16-42 months) with imatinib, and only 3 (8.3%) patients were exitus due to disease progression during the
follow-up (median: 43 months, IQR: 24.3-70.8). Conclusion: Our study provided clinical evidence of the efficacy and safety of imatinib in
patients with desmoid tumors with real-world experience. However, appropriately designed randomized-controlled clinical trials are needed
to explore the effectiveness of imatinib in desmoid tumors to provide an alternative management approach.
Keywords: Desmoid tumors; imatinib; efficacy